Patient demographic and baseline disease characteristics
| Baseline characteristics, (N = 12) . | . |
|---|---|
| Age, median (range) y | 41.5 (27-66) |
| Sex, female, n (%) | 9 (75.0) |
| Race, n (%) | |
| White | 8 (66.7) |
| Black or African American | 3 (25.0) |
| Asian | 1 (8.3) |
| Weight, kg [n = 11], mean (range) | 78.3 (57-114) |
| Disease duration at screening, y [n = 7], median (range) | 4.7 (2.0-36.4) |
| Platelet count,∗ median (range), ×109/L | 19 (1-57) |
| Number of prior treatments, median (range) | 5.5 (2-10) |
| Prior treatment received, n (%) | |
| Rituximab | 10 (83.3) |
| Corticosteroids | 8 (66.7) |
| TPO-RA | |
| Romiplostim | 8 (66.7) |
| Eltrombopag | 8 (66.7) |
| IVIg | 7 (58.3) |
| Fostamatinib | 2 (16.7) |
| Rilzabrutinib† | 1 (8.3) |
| Prior splenectomy, n (%) | 4 (33.3) |
| Baseline characteristics, (N = 12) . | . |
|---|---|
| Age, median (range) y | 41.5 (27-66) |
| Sex, female, n (%) | 9 (75.0) |
| Race, n (%) | |
| White | 8 (66.7) |
| Black or African American | 3 (25.0) |
| Asian | 1 (8.3) |
| Weight, kg [n = 11], mean (range) | 78.3 (57-114) |
| Disease duration at screening, y [n = 7], median (range) | 4.7 (2.0-36.4) |
| Platelet count,∗ median (range), ×109/L | 19 (1-57) |
| Number of prior treatments, median (range) | 5.5 (2-10) |
| Prior treatment received, n (%) | |
| Rituximab | 10 (83.3) |
| Corticosteroids | 8 (66.7) |
| TPO-RA | |
| Romiplostim | 8 (66.7) |
| Eltrombopag | 8 (66.7) |
| IVIg | 7 (58.3) |
| Fostamatinib | 2 (16.7) |
| Rilzabrutinib† | 1 (8.3) |
| Prior splenectomy, n (%) | 4 (33.3) |